Molecular Formula | C23H35N9O8S
|
Molar Mass | 597.64 |
Density | 1.443±0.06 g/cm3(Predicted) |
Boling Point | 1297.2±65.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 9.14±0.10(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
In vitro study | ATN-161 interaction with the N-terminus of the β1 region of integrin α5β1 locks integrin α5β1 in its inactive conformation. At concentrations up to 100 μm, ATN-161 had no significant effect on tumor cell proliferation. However, ATN-161 can significantly inhibit the phosphorylation of MAPK, and the maximum inhibition of MAPK phosphorylation can be detected at 30 minutes after treatment at a concentration of 20 μm. |
In vivo study | ATN-161 (Ac-PHSCN-NH2) is a 5-mer capping peptide derived from the cooperative region of fibronectin, which binds to α5β1 and αvβ3 in vitro to prevent breast cancer growth and metastasis. ATN-161 treatment can cause a significant reduction in tumor volume, dose-dependently, and can completely prevent or cause a reduction in the number and incidence of bone and soft tissue metastases. ATN-161 treatment can also lead to a decrease in phosphorylated MAPK expression in vivo, a decrease in microvessel density and cell proliferation during tumor growth. ATN-161 has a relatively short half-life in plasma. The relatively long half-life in tumors suggests that the peptide plays a role in tumors through a long-lasting interaction with its target. |